NA 901
Alternative Names: NA-901Latest Information Update: 17 Sep 2024
At a glance
- Originator NeuroActiva
- Class Antidementias; Antidepressants; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Major depressive disorder
- Preclinical Alzheimer's disease
Most Recent Events
- 09 Sep 2024 NA 901 is still in preclinical trial for Alzheimer's disease in USA
- 09 Sep 2024 Phase-I clinical trials in Major depressive disorder (unspecified route) before September 2024
- 09 Sep 2024 Efficacy and adverse events data from a phase Ib trial in Major depressive disorder released by NeuroActiva